Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)-Reference-Cited by-同舟云学术

Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)

Published:2023-10-19 Issue:6 Volume:10 Page:1683-1703
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Kameda Hideto^ORCID,Hagimori Kohei,Morisaki Yoji,Holzkämper Thorsten,Konomi Ayako^ORCID,Dobashi Hiroaki

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s40744-023-00605-6.pdf

Reference31 articles.

1. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22:40–55.

2. de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014;94:627–34.

3. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–70.

4. Taylor WJ. Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability. Curr Rheumatol Rep. 2012;14:369–74.

5. Food and Drug Administration. TALTZ (ixekizumab) injection, for subcutaneous use. 2016. Updated March 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s020lbl.pdf. Accessed Apr 18, 2023.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction: Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1);Rheumatology and Therapy;2024-05-16

2. Clinical Characteristics of “Severe” Peripheral Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort;Rheumatology and Therapy;2024-04-09